Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

riods was primarily the result of the recognition of product and research contract revenue from the Takeda collaboration and the recognition of licensing fee revenue for an extension fee payment under the agreement with PDL Biopharma Inc.

For the six-month period ended May 31, 2008, the Company's interest income decreased to $176,512 compared to $381,407 for the same period in fiscal 2007. For the three-month period ended May 31, 2008, the Company's interest income decreased to $69,720 compared to $181,484 for the same period in fiscal 2007. The decrease for both periods was primarily the result of lower average cash and investment balances.

For the six-month period ended May 31, 2008, the Company's research and development costs increased to $5,933,367 compared to $4,059,931 for the same period in fiscal 2007. For the three-month period ended May 31, 2008, the Company's research and development costs increased to $3,337,461 compared to $2,102,603 for the same period in fiscal 2007. The increases were primarily the result of an increase in staffing levels related to an overall increase in activity as the Company is preparing three products for the clinic, accompanied by increased patent and licensing activity and an increase in stock option remuneration expense.

For the six-month period ended May 31, 2008, the Company's general and administrative expenses increased to $2,170,683 compared to $1,437,009 for the same period in fiscal 2007. For the three-month period ended May 31, 2008, the Company's general and administrative expenses increased to $1,149,402 compared to $762,673 for the same period in fiscal 2007. The increases were primarily the result of an increase in staffing levels, consulting fees, legal expenses and stock option remuneration expense.

As at May 31, 2008, ARIUS' cash and cash equivalents, and net working capital position were $8,543,124 and $5,807,638, respectively, compared with November 30, 2007 cash and cash equivale
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
(Date:12/19/2014)... 2014 Charm Sciences is pleased to ... Detection of Aflatoxin M1 in raw commingled milk is ... party validation. The peer reviewed report of the validation ... for Agricultural and Fisheries Research (ILVO-T&V) has been published ... B1, the most toxic aflatoxin and a known carcinogen, ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... politics aside, every biologist knows that men and women truly ... area where those differences come to the fore: around 80 ... Social play behaviors also differ greatly between the sexes - ... girls. , ,Early in human development, critical brain proteins known ...
... The life sciences company Promega announced on Tuesday a ... that had been pending before the U.S. District Court ... Promega will hold a worldwide non-exclusive license from Benitec ... DNA-directed RNA interference (ddRNAi) technology. Promega will also receive ...
... an online provider of digital sheet music, announced on Tuesday ... Group to provide Word Music's collection of Christian music on ... , ,Word Music, a division of Warner Music Group based ... music from Christian songwriters such as Amy Grant, Point Of ...
Cached Biology Technology:Gender hormones may lend to social disorder therapies 2
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... July 2012, Apple introduced the fingerprint reading feature ... only device of Apple incorporating such a feature, ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... of the "Micro Market Monitor: North America Perimeter ... http://photos.prnewswire.com/prnh/20130307/600769 The ... at a CAGR of 3.6% from 2014 to 2019. ... this market, Canada is expected ...
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 323andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... , This release is available in ... discovered a mechanism that helps to explain resilience ... work. The new findings, in the reward circuit ... high tech dragnet for compounds that boost the ...
... Researcher in the University of Bristol,s School of Biological Sciences ... as a cue to find coral reefs, but was amazed ... larvae which must quickly find a safe place to ... can do the same thing. The team designed a ...
... For years, researchers have known that resistance exercise training ... another force can be one of the most effective ... But many older people are unable to get the full ... as arthritis that prevent them from lifting enough weight to ...
Cached Biology News:Resilience factor low in depression, protects mice from stress 2Resilience factor low in depression, protects mice from stress 3Muscle mass in elderly boosted by combining resistance exercise and blood flow restriction 2